Clinical trial
VNP20009 in Treating Patients With Advanced Solid Tumors
NCT00006254 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00006254 |
|---|---|
| Title | VNP20009 in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | salmonella VNP20009 |
| Start date | May 1, 2000 |
| Completion | Jan 1, 2008 |
| First posted | Sep 3, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: